Ligand Pharmaceuticals logo

Ligand Pharmaceuticals share price today

(LGND)

Ligand Pharmaceuticals share price is $107.92 & ₹9,260.62 as on 7 Jan 2025, 2.30 'hrs' IST

$107.92

-2.64

(-2.39%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Ligand Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Ligand Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ligand Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Ligand Pharmaceuticals share price movements

  • Today's Low: $107.55
    Today's High: $112.61

    Day's Volatility :4.49%

  • 52 Weeks Low: $67.53
    52 Weeks High: $129.90

    52 Weeks Volatility :48.01%

Ligand Pharmaceuticals Returns

PeriodLigand Pharmaceuticals IncorporatedSector (Health Care)Index (Russel 2000)
3 Months
7.37%
-8.4%
0.0%
6 Months
20.55%
-3.8%
0.0%
1 Year
48.7%
-0.1%
0.0%
3 Years
-24.71%
2.9%
-19.8%

Ligand Pharmaceuticals Key Statistics

in dollars & INR

Previous Close
$110.56
Open
$110.61
Today's High
$112.61
Today's Low
$107.55
Market Capitalization
$2.0B
Today's Volume
$80.5K
52 Week High
$129.9
52 Week Low
$67.53
Revenue TTM
$152.4M
EBITDA
$52.6M
Earnings Per Share (EPS)
$2.49
PE Ratio
43.03
Profit Margin
29.68%
Quarterly Earnings Growth YOY
1.03%
Return On Equity TTM
6.0%

How to invest in Ligand Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Ligand Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ligand Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ligand Pharmaceuticals or LGND on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ligand Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ligand Pharmaceuticals shares which would translate to 0.008 fractional shares of Ligand Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ligand Pharmaceuticals, in just a few clicks!

Returns in Ligand Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ligand Pharmaceuticals investment value today

Current value as on today

₹1,48,374

Returns

₹48,374

(+48.37%)

Returns from Ligand Pharmaceuticals Stock

₹45,151 (+45.15%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Ligand Pharmaceuticals

-9%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Ligand Pharmaceuticals on INDmoney from India has reduced in the last 30 days as on Jan 7, 2025. -9% less investors are searching Ligand Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Ligand Pharmaceuticals

  • BlackRock Inc

    15.20%

  • Vanguard Group Inc

    10.43%

  • HHG PLC

    5.34%

  • Macquarie Group Ltd

    4.70%

  • State Street Corp

    3.74%

  • Dimensional Fund Advisors, Inc.

    3.74%

Analyst Recommendation on Ligand Pharmaceuticals

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Ligand Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Ligand Pharmaceuticals

What analysts predicted

Upside of 33.43%

Current:

$107.92

Target:

$144.00

Insights on Ligand Pharmaceuticals

  • Price Movement

    In the last 1 month, LGND stock has moved down by -11.4%
  • Increasing Revenue

    Revenue is up for the last 4 quarters, 28.10M → 51.81M (in $), with an average increase of 18.2% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -51.91M → -7.17M (in $), with an average increase of 623.8% per quarter
  • LGND vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 78.7%

Ligand Pharmaceuticals Financials in INR & Dollars

FY18Y/Y Change
Revenue
$251.5M
↑ 78.21%
Net Income
$143.3M
↑ 1041.45%
Net Profit Margin
57.0%
↑ 48.1%
FY19Y/Y Change
Revenue
$120.3M
↓ 52.17%
Net Income
$629.3M
↑ 339.09%
Net Profit Margin
523.19%
↑ 466.19%
FY20Y/Y Change
Revenue
$186.4M
↑ 54.98%
Net Income
$-3.0M
↓ 100.47%
Net Profit Margin
-1.6%
↓ 524.79%
FY21Y/Y Change
Revenue
$277.1M
↑ 48.66%
Net Income
$57.1M
↓ 2014.17%
Net Profit Margin
20.62%
↑ 22.22%
FY22Y/Y Change
Revenue
$196.2M
↓ 29.19%
Net Income
$-5.2M
↓ 109.13%
Net Profit Margin
-2.66%
↓ 23.28%
FY23Y/Y Change
Revenue
$131.3M
↓ 33.09%
Net Income
$52.2M
↓ 1099.31%
Net Profit Margin
39.72%
↑ 42.38%
Q2 FY23Q/Q Change
Revenue
$26.4M
↓ 40.05%
Net Income
$2.3M
↓ 94.54%
Net Profit Margin
8.69%
↓ 86.69%
Q3 FY23Q/Q Change
Revenue
$32.9M
↑ 24.66%
Net Income
$-12.8M
↓ 658.6%
Net Profit Margin
-38.92%
↓ 47.61%
Q4 FY23Q/Q Change
Revenue
$28.1M
↓ 14.5%
Net Income
$18.2M
↓ 242.18%
Net Profit Margin
64.72%
↑ 103.64%
Q1 FY24Q/Q Change
Revenue
$31.0M
↑ 10.24%
Net Income
$86.1M
↑ 373.6%
Net Profit Margin
278.07%
↑ 213.35%
Q2 FY24Q/Q Change
Revenue
$41.5M
↑ 34.07%
Net Income
$-51.9M
↓ 160.26%
Net Profit Margin
-124.99%
↓ 403.06%
Q3 FY24Q/Q Change
Revenue
$51.8M
↑ 24.76%
Net Income
$-7.2M
↓ 86.18%
Net Profit Margin
-13.84%
↑ 111.15%
FY18Y/Y Change
Profit
$245.1M
↑ 80.58%
FY19Y/Y Change
Profit
$108.9M
↓ 55.56%
FY20Y/Y Change
Profit
$156.0M
↑ 43.2%
FY21Y/Y Change
Profit
$215.0M
↑ 37.79%
FY22Y/Y Change
Profit
$143.4M
↓ 33.28%
FY23Y/Y Change
Profit
$96.3M
↓ 32.88%
Q2 FY23Q/Q Change
Profit
$24.7M
↓ 38.66%
Q3 FY23Q/Q Change
Profit
$29.4M
↑ 18.97%
Q4 FY23Q/Q Change
Profit
$26.4M
↓ 10.03%
Q1 FY24Q/Q Change
Profit
$19.9M
↓ 24.69%
Q2 FY24Q/Q Change
Profit
$30.4M
↑ 52.53%
Q3 FY24Q/Q Change
Profit
$39.3M
↑ 29.47%
FY18Y/Y Change
Operating Cash Flow
$194.1M
↑ 107.4%
Investing Cash Flow
$-423.3M
↑ 402.83%
Financing Cash Flow
$328.6M
↓ 4467.74%
FY19Y/Y Change
Operating Cash Flow
$-29.3M
↓ 115.12%
Investing Cash Flow
$466.9M
↓ 210.31%
Financing Cash Flow
$-485.2M
↓ 247.65%
FY20Y/Y Change
Operating Cash Flow
$54.6M
↓ 286.07%
Investing Cash Flow
$231.6M
↓ 50.39%
Financing Cash Flow
$-310.5M
↓ 35.99%
FY21Y/Y Change
Operating Cash Flow
$78.8M
↑ 44.36%
Investing Cash Flow
$30.5M
↓ 86.82%
Financing Cash Flow
$-137.8M
↓ 55.64%
FY22Y/Y Change
Operating Cash Flow
$137.9M
↑ 74.94%
Investing Cash Flow
$163.6M
↑ 436.07%
Financing Cash Flow
$-276.0M
↑ 100.34%
Q2 FY23Q/Q Change
Operating Cash Flow
$-82.0K
↓ 100.24%
Investing Cash Flow
$7.6M
↓ 28.37%
Financing Cash Flow
$-67.8M
↑ 8642.84%

Ligand Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Ligand Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ligand Pharmaceuticals Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ligand Pharmaceuticals Incorporated
-4.97%
20.55%
48.7%
-24.71%
15.54%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ligand Pharmaceuticals Incorporated
43.03
43.03
1.53
5.66
0.06
0.01
NA
44.84
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ligand Pharmaceuticals Incorporated
Buy
$2.0B
15.54%
43.03
29.68%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Ligand Pharmaceuticals

ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Organization
Ligand Pharmaceuticals
Employees
58
CEO
Mr. Todd C. Davis Ph.D.
Industry
Health Technology

Management People of Ligand Pharmaceuticals

NameTitle
Mr. Todd C. Davis Ph.D.
CEO & Director
Mr. Octavio Espinoza
Chief Financial Officer
Mr. Andrew T. Reardon J.D.
Chief Legal Officer & Secretary
Mr. Paul J. Hadden
Senior Vice President of Investments & Business Development
Michael Jeong
Head of Investor Relations
Mr. Todd Pettingill C.F.A.
Director of Corporate Development
Dr. Keith Marschke
Senior Vice President of Biology & Scientific Affairs
Dr. Vincent D. Antle
Senior Vice President of Technical Operations & QA - Capitsol
Mr. Patrick Lucy
Senior VP & CBO Protein Expression Business
Dr. Karen R. Reeves M.D.
Senior VP of Investments & Head of Clinical Strategy

Important FAQs about investing in Ligand Pharmaceuticals from India :

What is Ligand Pharmaceuticals share price today?

Ligand Pharmaceuticals share price today stands at $107.92, Open: $110.61 ; Previous Close: $110.56 ; High: $112.61 ; Low: $107.55 ; 52 Week High: $129.90 ; 52 Week Low: $67.53. The stock opens at $110.61, after a previous close of $110.56. The stock reached a daily high of $112.61 and a low of $107.55, with a 52-week high of $129.90 and a 52-week low of $67.53.

Can Indians buy Ligand Pharmaceuticals shares?

Yes, Indians can invest in the Ligand Pharmaceuticals (LGND) from India.

With INDmoney, you can buy Ligand Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Ligand Pharmaceuticals at zero transaction cost.

How can I buy Ligand Pharmaceuticals shares from India?

It is very easy to buy Ligand Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ligand Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Ligand Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Ligand Pharmaceuticals stocks?

To start investing in Ligand Pharmaceuticals, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Ligand Pharmaceuticals

Today’s highest price of Ligand Pharmaceuticals (LGND) is $112.61.

Today’s lowest price of Ligand Pharmaceuticals (LGND) is $107.55.

What is today's market capitalisation of Ligand Pharmaceuticals

Today's market capitalisation of Ligand Pharmaceuticals LGND is 2.0B

What is the 52 Week High and Low Range of Ligand Pharmaceuticals

  • 52 Week High

    $129.90

  • 52 Week Low

    $67.53

What are the historical returns of Ligand Pharmaceuticals?

  • 1 Month Returns

    -4.97%

  • 3 Months Returns

    20.55%

  • 1 Year Returns

    48.7%

  • 5 Years Returns

    15.54%

Who is the Chief Executive Officer (CEO) of Ligand Pharmaceuticals

Mr. Todd C. Davis Ph.D. is the current Chief Executive Officer (CEO) of Ligand Pharmaceuticals.